Tess O’Meara, MD, highlights the role of antibody-drug conjugates for the treatment of patients with HER2-positive breast cancer.
Tess O'Meara, MD
Advertisement
Tess O’Meara, MD, is a clinical fellow in medicine at the Dana-Farber Cancer Institute in Boston, Massachusetts.
Articles by Tess O'Meara, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Dr Le on Choosing Between Zongertinib and Sevabertinib in HER2 TKD–Mutant NSCLC
4
Innovative Screening Approaches, Targeted Therapies, and Team-Based Care Drive Head and Neck Oncology Advances
5